Publication: Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience
No Thumbnail Available
Date
2024-05-21
Authors
Authors
HAMDARD J.
BİLİCİ A.
Sakin A.
Kahraman S.
YASİN A. İ.
KALACI E.
Gokmen I.
AÇIKGÖZ Ö.
KUTLU Y.
Sendur M. A. N.
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Abstract
We evaluated the incidence, clinicopathological features, prognostic factors, progression-free survival (PFS) and overall survival (OS) of patients with gastric cancer and bone metastases. The medical records of 110 patients with bone metastases were retrospectively analyzed. In our study, the incidence of bone metastases was 3.2%. The median patient age was 60 years. A total of 68 (61.8%) patients exhibited synchronous metastases, and 42 (38.2%) patients developed metachronous metastases. Alkaline phosphatase (ALP) levels were high in 54 (49%) patients. At the median follow-up time of 9.8 months, median PFS and OS times were 4.7 and 6.3 months, respectively. The median interval from the diagnosis to bone metastases was 9.3 months. Univariate analysis showed that Eastern Cooperative Oncology Group Performance Status (ECOG PS) >= 2, stage at diagnosis, time of metastases, number of metastases, presence of extraskeletal metastases, use of zoledronic acid treatment, palliative chemotherapy post-bone metastases and radiotherapy to bone metastases were significant prognostic indicators for PFS. Additionally, ECOG PS >= 2, stage at diagnosis, time of metastases, number of metastases, presence of extraskeletal metastases, zoledronic acid treatment, palliative chemotherapy post-bone metastases, and radiotherapy to bone metastases significantly influenced OS. Moreover, in multivariate analysis, ECOG PS, time of metastases, presence of extra-bone metastases, and the use of palliative chemotherapy after bone metastases were found to be independent prognostic factors for PFS. Moreover, ECOG PS, time of metastases, and use of palliative chemotherapy after bone metastases were significantly independent prognostic indicators for OS. Our findings show that the presence of synchronous metastases, use of palliative chemotherapy, use of zoledronic acid after bone metastases, and ALP level within the normal range were significantly associated with prolonged OS in gastric cancer patients with bone metastases.
Description
Keywords
Tıp, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji, Cerrahi Tıp Bilimleri, Patoloji, Eczacılık, Temel Eczacılık Bilimleri, Yaşam Bilimleri, Sağlık Bilimleri, Temel Tıp Bilimleri, Biyokimya, Temel Bilimler, Medicine, Internal Medicine Sciences, Internal Diseases, Oncology, Surgery Medicine Sciences, Pathology, Pharmacology and Therapeutics, Basic Pharmaceutics Sciences, Life Sciences, Health Sciences, Fundamental Medical Sciences, Biochemistry, Natural Sciences, ONKOLOJİ, Klinik Tıp, Klinik Tıp (MED), BULAŞICI HASTALIKLAR, İmmünoloji, Yaşam Bilimleri (LIFE), PATOLOJİ, Biyoloji ve Biyokimya, FARMAKOLOJİ VE ECZACILIK, Farmakoloji ve Toksikoloji, ONCOLOGY, CLINICAL MEDICINE, Clinical Medicine (MED), INFECTIOUS DISEASES, IMMUNOLOGY, Life Sciences (LIFE), PATHOLOGY, BIOLOGY & BIOCHEMISTRY, PHARMACOLOGY & PHARMACY, PHARMACOLOGY & TOXICOLOGY, Farmakoloji, Farmakoloji, Toksikoloji ve Eczacılık (çeşitli), Genel Farmakoloji, Toksikoloji ve Eczacılık, Farmakoloji (tıbbi), Patoloji ve Adli Tıp, Bulaşıcı hastalıklar, Histoloji, İlaç Rehberleri, Biyokimya (tıbbi), Genel İmmünoloji ve Mikrobiyoloji, Pharmacy, Pharmacology, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), General Pharmacology, Toxicology and Pharmaceutics, Pharmacology (medical), Pathology and Forensic Medicine, Infectious Diseases, Histology, Drug Guides, Biochemistry (medical), Immunology, General Immunology and Microbiology
Citation
HAMDARD J., BİLİCİ A., Sakin A., Kahraman S., YASİN A. İ., KALACI E., Gokmen I., AÇIKGÖZ Ö., KUTLU Y., Sendur M. A. N., et al., "Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience", JOURNAL OF CHEMOTHERAPY, 2024